Skip to main content
Blizard Institute - Barts and The London

Professor Klaus Schmierer, MB BS, PhD, FRCP


Professor of Neurology

Centre: Neuroscience and Trauma

Telephone: 020 7882 6246


Dr Schmierer has a special interest in demyelinating diseases of the central nervous system, particularly multiple sclerosis (MS), in research and clinical practice. The work by his group focusses on a better understanding of MS pathogenesis, particularly chronic disease deterioration (“progressive MS”), and treatment of people with MS. Dr Schmierer’s research is translational with the intention to transform disease modifying treatment of people with MS across all disease stages globally.


MS has been a focus of Dr Schmierer’s clinical and research activities from the beginning of his training in Neurology at the Charité Hospital (Humboldt University Berlin), which followed undergraduate studies in Berlin and Jerusalem. In 2001 he moved to London to pursue a career in academic neurology, initially as a Research Fellow, and from 2005 as a Wellcome Intermediate Clinical Fellow at the UCL Institute of Neurology, and a Consultant Neurologist at The National Hospital, Queen Square. Here, he investigated histo-pathological correlates of quantitative MRI using standard and high-field MR systems to improve disease monitoring in people with MS. Following appointments in 2009 at Queen Mary University of London (QMUL) and The Royal London Hospital (Barts Health NHS Trust) his clinical academic work now includes:

  • exploring the pathological substrate of disease deterioration in pwMS using MRI and quantitative histology;
  • studies into the epidemiology and cause(s) of MS/the BartsMS Database;
  • in vivo MRI studies to improve the differential-diagnosis of MS, and
  • investigator-led and commercial clinical trials. Research by his group has been supported by the Higher Education Funding Council for England, the Wellcome Trust, Barts Charity, the Royal College of Radiologists, UK MS Society, the National MS Society (US), MRC, NIHR and the pharmaceutical industry.

From 2013-15 Dr Schmierer served as a member of the Association of British Neurologists’ MS & Neuroinflammation Specialist Subcommittee which published the latest UK disease modifying treatment guidelines for people with MS. He has been the Deputy Director of the Research & Development Board in the Emergency Care & Acute Medicine Clinical Academic Group of Barts Health NHS Trust. He is the Past-Chair of the White Matter Study Group of the International Society for Magnetic Resonance in Medicine, and serves on the MS Society’s Clinical Trials Network, their Consortium for progressive MS, as well as the review board of the MS Register. Dr Schmierer is the sub speciality lead for MS at the NIHR North Thames Clinical Research Network, and acts as an advisor to the EMA, MHRA and NICE on new drugs for MS.

BartsMS Blog:

BartsMS Charity:






MBBS years 1, 2 & 4

 Lead SSC Neuroinflammation & MS years 2, 4 and 5

 MSc & PhD supervision


Research Interests:

  • Exploring the pathological substrate of disease deterioration in pwMS using MRI and quantitative histology
  • Understanding the pathophysiology, and potential as biomarkers, of lymphocyte subtypes, and their relevance for disease activity in people with MS
  • Studies into the epidemiology and cause(s) of MS/the BartsMS Database
  • In vivo MRI studies to improve the differential-diagnosis of MS
  • Investigator-led and commercial clinical trials


Research Group

  • Stefania De Trane MD, Clinical Research Fellow
  • Ozlem Yildiz MD, Clinical Research Fellow
  • Daniel R Altmann DPhil, Associate Professor of Statistics
  • Kimberley Allen-Philbey MSc, Clinical Trials Practitioner
  • Maria Espasandin MSc, Research Manager & Nurse Lead, Neurosciences Day Case Unit
  • Natalia Petrova MSc, Postdoctoral Researcher
  • Francesco Scaravilli PhD, Emeritus Professor of Neuropathology
  • Benjamin Meir Jacobs MRCP, Academic FY2
  • Christo Albor PhD, Academic FY1
  • Dayo Afolabi BSc, Medical Student


  • Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 2017;74:961-9.
  • Petrova N, Carassiti D, Baker D, Scaravilli F, Schmierer K.  Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol 2017 Apr 12. doi: 10.1111/bpa.12516. [Epub ahead of print]
  • Carassiti D, Altmann DR, Pakkenberg B, Scaravilli F, Schmierer K.  Neuronal loss, demyelination and volume change across the multiple sclerosis neocortex. Neuropathol Appl Neurobiol 2017 Apr 18. doi: 10.1111/nan.12405. [Epub ahead of print]
  • Campion T, Smith RJP, Altmann DR, Brito GC, Turner BP, Evanson J, George IC, Sati P, Reich DS, Miquel ME, Schmierer K. FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis? Eur Radiol 2017 Apr 13. doi: 10.1007/s00330-017-4822-z. [Epub ahead of print]
  • Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 2017;16:41-50.
  • Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm 2015;2:e158.
  • Davis AG, Dobson R, Kaninia S, Espasandin M, Berg A, Giovannoni G, Schmierer K.  Change practise now! Using atraumatic needles for prevention of post lumbar puncture headache. Eur J Neurol 2014;21:305-11.
  • Schmierer K, Parkes HG, So P-W, An SF, Brandner SA, Ordidge RJ, Yousry TA, Miller DH. High field (9.4 Tesla) magnetic resonance imaging of multiple sclerosis cortical grey matter lesions. Brain 2010;133:858-67.
  • Schmierer K, Wheeler-Kingshott CAM, Boulby PA, Scaravilli F, Altmann DR, Barker GJ, Tofts PS, Miller DH. Diffusion tensor imaging of post mortem multiple sclerosis brain. NeuroImage 2007;35:467-77.
  • Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56:407-415.
  • Schmierer K, Irlbacher K, Grosse P, Röricht S, Meyer B-U. Correlates of disability in multiple sclerosis detected by transcranial magnetic stimulation. Neurology 2002;59:1218-24.
  • Schmierer K, Niehaus L, Röricht S, Meyer B-U. Conduction deficits of callosal fibres in early multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:633-8.

View all Klaus Schmierer's Research Publications at: